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MicroRNA miR-155 Is Necessary for Efficient Gammaherpesvirus
Reactivation from Latency, but Not for Establishment of Latency
Rebecca L. Crepeau, Peisheng Zhang, Edward J. Usherwood
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA
ABSTRACT
MicroRNA-155 (miR-155) has been shown to play significant roles in the immune response, including in the formation of germi-
nal centers (GC) and the development and maturation of T follicular helper (Tfh) cells. There is in vitro evidence to support a
critical role for cellular miR-155 and viral miR-155 homologs in the establishment of gammaherpesvirus latency in B cells. We
sought to determine the contribution of miR-155 to the establishment and maintenance of latency in vivo using murine gamma-
herpesvirus (MHV-68) infection. MHV-68-infected mice deficient in miR-155 exhibited decreases in GC B cells and Tfh cells.
However, the frequencies of spleen cells harboring latent MHV-68 genomes were the same in both miR-155-deficient and wild-
type (WT) mice. Similar latent loads were also observed in mixed bone marrow chimeric mice, where B cell-extrinsic effects of
miR-155 deficiency were normalized. Interestingly, we observed markedly lower efficiency of reactivation from latency in miR-
155-deficient cells, indicating an important role for miR-155 in this process. These in vivo data complement previous in vitro
studies and lead to the conclusion that miR-155 is not necessary for the establishment or maintenance of gammaherpesvirus
latency but that it does affect reactivation efficiency.
IMPORTANCE
Gammaherpesvirus infection leads to severe disease in immunosuppressed populations. miR-155 has been shown to play impor-
tant roles in many pathological processes, including tumorigenesis and diseases caused by an overly aggressive immune re-
sponse. Our work provides valuable in vivo data showing that miR-155 is dispensable for gammaherpesvirus latency but that it
is critical for reactivation from latency, which is a crucial step in the viral life cycle.
The herpesvirus family is a large and widely distributed family ofdouble-stranded, enveloped DNA viruses. Their anatomical
sites of latency and frequency of reactivation vary, resulting in a
range of clinical manifestations. A defining feature of this virus
family is the ability to establish latent infection within host cells.
The gammaherpesviruses distinguish themselves by being lym-
photropic, in most cases establishing latency in B cells, where co-
ordinated programs of viral and host gene expression promote B
cell differentiation to favor virus latency.
Gammaherpesviruses are of clinical interest due to the two
human members of this viral subfamily: Epstein-Barr virus (EBV;
human herpesvirus 4 [HHV-4]) and Kaposi’s sarcoma-associated
herpesvirus (KSHV; HHV-8). These viruses are closely associated
with the development of malignancies in immunosuppressed
populations. EBV was initially recovered from an endemic form of
Burkitt’s lymphoma, and it has been shown to hijack the B cell
differentiation pathway in order to gain access into the long-lived
memory B cell compartment (1). Due to the narrow host tropism
and seroprevalence of the human gammaherpesviruses, murine
gammaherpesvirus (MHV-68) has become a critical model system
in which to examine the in vivo immunobiology of the gamma-
herpesviruses. Like its human counterparts, MHV-68 is a lympho-
tropic, double-stranded DNA virus that establishes latency in B
cells (2, 3), primarily in the spleen.
Herpesviruses establish latent infection within host cells in or-
der to persist for the lifetime of the host. Viral gene expression
must be silenced in this state to avoid immune recognition; the
virus must also modulate host cell functions, such as cellular life
span, proliferation, and differentiation, in order to promote the
latent state. To evade the immune response, the timing and
amount of virus replication must be controlled. One of the ways in
which this can occur is through the carefully choreographed ex-
pression of viral genes through posttranscriptional regulation via
microRNAs (miRNAs).
By their ability to regulate large groups of genes simultane-
ously, miRNAs are attractive targets for viral manipulation to alter
host cell processes. This class of small RNAs consists of regulatory,
noncoding RNAs that bind to their mRNA targets and either block
their translation or initiate their degradation. They do so through
imperfect complementary base pairing in the 3= untranslated re-
gion (UTR) (4). miRNAs have been shown to play important roles
in various cellular and pathogenic processes, including cellular
development and maturation, various immunological responses,
and tumorigenesis (5–7).
The gammaherpesviruses encode multiple miRNAs which
may mimic cellular miRNAs and modulate both cellular and viral
gene expression as well as cellular miRNA expression. One
microRNA in particular, miR-155, has been shown to control a
wide range of immunological functions including T and B cell
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activation, inflammation, and immunological memory (8). Inter-
estingly, KSHV and also the alphaherpesvirus Marek’s disease vi-
rus encode viral homologs for cellular miR-155, indicating its
likely role in herpesvirus pathogenesis. The KSHV homolog, miR-
K12-11, as well as the Marek’s disease virus homolog, mdv1-miR-
M4, share 100% seed sequence specificity with human miR-155
and also have been shown to regulate a common set of target genes
(9–11).
Mature miR-155 is derived from the B cell integration cluster
(BIC)-associated noncoding RNA precursor (12). This gene was
originally identified as a common retroviral insertion site for avian
leukosis virus-induced B cell lymphomas (13). Despite the fact
that EBV does not encode a viral homolog to miR-155, both the
precursor BIC and, subsequently, the mature miR-155 transcripts
have been shown to be overexpressed in EBV-infected cells as well
as in a variety of EBV-associated B cell malignancies, indicating
viral regulation of this cellular microRNA (14–16). Additionally,
this overexpression was found to be induced by viral genes (14).
When miR-155 was selectively inhibited in EBV-positive tumor
cell lines in vitro, these cells failed to proliferate and underwent a
higher rate of apoptosis, indicating a role for this microRNA in
driving immortalization (17).
While previous studies have suggested an important role for
miR-155 in the promotion of gammaherpesvirus latency, these
studies largely relied on in vitro experiments. In this report we use
MHV-68 infection to test whether the absence of cellular miR-155
in B cells affects latent infection in vivo. We find that both latency
establishment and maintenance occur comparably in the absence
of miR-155. However, in this setting, reactivation from latency
occurs with lower efficiency, suggesting an important role for this
miRNA in reemergence of the virus from the latent state. To date,
few host factors have been found to influence latency and reacti-
vation. This study provides evidence that host cellular miR-155
plays a critical role in reactivation from latency, a crucial step in
the viral life cycle.
MATERIALS AND METHODS
Mice and virus. C57BL/6 (B6) and B6-Ly5.2 mice were purchased
from the National Cancer Institute (Bethesda, MD). The B6.Cg-
Mir155tm1.1Rsky/J strain (denoted miR-155 KO, where KO is knockout)
was purchased from The Jackson Laboratories (Bar Harbor, ME) and bred
in the Dartmouth-Hitchcock Medical Center animal facility. Mice were
maintained under specific-pathogen-free conditions in the Dartmouth
Center for Comparative Medicine and Research. The Animal Care and
Use Committee of Dartmouth College approved all animal experiments.
MHV-68 clone G2.4 was obtained from A. A. Nash (University of
Edinburgh, Edinburgh, United Kingdom). The viral strains were propa-
gated, and titers were determined using NIH 3T3 cells, as previously de-
scribed (18). A transgenic strain of MHV-68 harboring a fusion protein
composed of the enhanced yellow fluorescent protein (EYFP) coding se-
quence fused to the histone H2b open reading frame, MHV-68 –H2bYFP,
was also used in order to determine the population of latently infected B
cells. This strain was kindly provided by Samuel Speck (Emory University,
Atlanta, GA). Mice were infected intranasally with 4,000 PFU MHV-68 or
MHV-68 –H2bYFP under anesthesia with isoflurane.
Generation of mixed BM chimeric mice. B6-Ly5.2 recipient mice
were lethally irradiated with 1,000 rads (500 rads twice, given 24 h apart)
and subsequently injected intravenously (i.v.) with a total of 1  106 to
2  106 bone marrow (BM) cells containing a mixture of B6-Ly5.2
(CD45.1) and miR-155 KO (CD45.2) cells at a 1:1 ratio. Reconstitu-
tion of the BM was checked at 5 weeks post-BM transfer by staining blood
cells for the congenic markers.
Tissue and cell preparations. Splenocytes were prepared by passing
spleens through cell strainers, and red blood cells (RBCs) were lysed using
Gey’s solution.
Plaque assay. Infectious virus titers in the lungs were determined by
plaque assays as previously described (18). Briefly, lungs were homoge-
nized and frozen at 80°C at 7, 8.5, or 10 days postinfection (dpi). Serial
dilutions of homogenized lung tissues were added to NIH 3T3 monolay-
ers in a minimal volume and left to adsorb for 1 h before samples were
overlaid with carboxymethyl cellulose. After 5 days of incubation at 37°C,
the assays were fixed with methanol and stained with Giemsa stain, and
plaques were enumerated microscopically.
Virus neutralization assay. Blood was collected from mice latently
infected with MHV-68 at 28 days postinfection. Six 3-fold dilutions of
serum were made in duplicate, starting at a 1/10 dilution. The diluted
serum samples were mixed with 50 PFU of MHV-68 and incubated at
room temperature for 1 h. One hundred microliters of the mixture plus
400 l of complete medium was then added to NIH 3T3 monolayers,
which were then incubated at 37°C for 1 h. Two milliliters of medium
containing carboxymethyl cellulose was then added, and the plates were
cultured for 5 days at 37°C. On the sixth day, monolayers were fixed with
methanol for 1 h and stained with Giemsa stain, and plaques were counted
microscopically. The percentage of neutralization was calculated based on
the maximum number of plaques in the no-serum control.
-Gal/LacZ assay. For detection of -galactosidase (-Gal) activity,
cells were stained with the -galactosidase substrate resorufin -D-galac-
topyranoside (RDG; Marker Gene, Inc., Eugene, OR). Briefly, splenocytes
were harvested at 14 days postinfection and processed into a single-cell
suspension of 2  107 cells/ml. One hundred microliters of prewarmed
cell samples was loaded with 100 l of 2 mM prewarmed RDG at 37° for 1
min. The reaction was stopped by mixing loaded samples with 2 ml of
ice-cold Hanks balanced salt solution (HBSS) containing 2% serum, 10
mM HEPES, and 1% penicillin-streptomycin (HBSS). Loaded cell sam-
ples were kept on ice for 1.5 h to allow accumulation of fluorochrome
release from RDG in LacZ cells. Samples were then pelleted and resus-
pended in 100 l of ice-cold HBSS. Samples were then stained with
antibody markers of germinal center (GC) B cells as stated above and
analyzed using the MACSQuant instrument in the DartLab core facility
(Dartmouth College) or an Accuri flow cytometer. Data were analyzed
using FlowJo software (TreeStar, Ashland, OR) or Accuri software (BD
Biosciences).
Abs and flow cytometry. Antibodies (Abs) for flow cytometric analy-
sis were purchased from eBioscience (San Diego, CA), BD Biosciences
(San Jose, CA), or Biolegend (San Diego, CA). In germinal center B cells
the following were used: T and B cell activation marker conjugated to
phycoerythrin (GL7), CD19 conjugated to peridinin-chlorophyll protein-
Cy5.5 (ID3), and CD95 conjugated to allophycocyanin (APC) (15A7). In
plasma cells, the following were used: CD138 conjugated to phycoerythrin
(281-2), CD3 conjugated to peridinin-chlorophyll protein-Cy5.5 (145-
2C11), and B220 conjugated to Pacific blue (RA-3-6B2). In T follicular
helper cells, the following were used: CD4 conjugated to allophycocyanin-
eFluor 780 (GK1.5), purified CXCR5 (2G8), PD-1 conjugated to fluo-
rescein isothiocyanate (FITC) (J43), BCL-6 conjugated to peridinin-
chlorophyll protein-Cy5.5 (K112-91), biotin-conjugated Affinipure
goat anti-rat IgG(HL) (Jackson ImmunoResearch), and streptavidin-
APC. Samples were analyzed using the MACSQuant instrument in the
DartLab core facility (Dartmouth College) or Accuri flow cytometer. Data
were analyzed using FlowJo software (TreeStar, Ashland, OR) or Accuri
software (BD Biosciences).
Surface markers on cells were stained with Abs in phosphate-buffered
saline (PBS) with 2% bovine growth serum ([BGS]; fluorescence-assisted
cell sorting [FACS] buffer) at 4°C for 20 min. Tfh cells were stained with
purified CXCR5 for 1 h in PBS plus 0.5% bovine serum albumin (BSA)
plus 2% normal mouse serum (NMS) plus 2% BGS, followed by biotin-
goat anti-rat IgG for 30 min in FACS buffer plus 2% NMS plus 2% BGS
and then by streptavidin and additional surface-staining Abs for 30 min in
Crepeau et al.
7812 jvi.asm.org September 2016 Volume 90 Number 17Journal of Virology
FACS buffer plus 2% NMS plus 2% BGS at 4°C. A Foxp3/transcription
factor staining buffer set (eBioscience) was used for transcription factor
detection.
Quantitative PCR (qPCR) for viral load. Latent viral DNA was quan-
tified by quantitative fluorescent PCR (QF-PCR) as previously described
(19). Briefly, DNA was extracted from whole splenocytes or sorted B cells
using a Qiagen DNeasy kit (Qiagen, Valencia, CA) and then quantified
using a UV spectrophotometer. DNA (300 ng) was subjected to QF-PCR
using Platinum Quantitative PCR SuperMix-UDG (Invitrogen, Carlsbad,
CA), 500 nM primers complementary to the ORF50 gene, and 200 nM
labeled probe complementary to the ORF50 gene. The samples were sub-
jected to 40 cycles of 15 s at 95°C and 1 min at 60°C. QF-PCR was per-
formed using a Bio-Rad iCycler (Bio-Rad, Hercules, CA). To construct a
standard curve, a graded number of copies of the pTW-27 plasmid, con-
taining the genomic ORF50 gene, was mixed with 300 ng of normal
splenocyte DNA and subjected to QF-PCR. No-template controls con-
taining 300 ng of uninfected splenocyte DNA were negative for all QF-
PCR assays. The assay was able to detect fewer than 10 viral genomes per
sample.
Total serum IgG ELISA. Blood was collected from mice latently in-
fected with MHV-68 at 28 to 30 days postinfection. Serum samples were
subjected to a mouse IgG total Ready-Set-Go enzyme-linked immunosor-
bent assay (ELISA) as instructed by the manufacturer (eBioscience, San
Diego, CA). Briefly, Corning Costar 9018 ELISA plates (Corning, NY)
were coated at 4° overnight with the provided capture antibody. The plate
was washed, and wells were blocked for 2 h at room temperature with the
provided blocking buffer. A standard curve was generated using 2-fold
serial dilutions of the standard in 1 assay buffer A. Samples at a 1:1,000
dilution were added to the designated wells, followed by the provided
detection antibody. The plate was covered and incubated at room tem-
perature for 3 h, at which point substrate was added and allowed to incu-
bate at room temperature. Reactions were stopped after 15 min and read
at a wavelength of 450 nm.
LDA measuring frequency of free or reactivatable virus. Limiting-
dilution assays (LDAs) were performed as described previously (20). Pri-
mary mouse embryonic fibroblasts (MEF) were added to flat-bottomed
96-well plates (104 cells/well) and cultured overnight. A spleen cell sus-
pension was prepared using organs from infected mice, and graded num-
bers of cells (100,000 to 780 cells/well) were added to the MEF monolay-
ers. Twenty-four replicate wells were used per dilution of spleen cells. The
plates were cultured for 2 weeks at 37°C and then examined microscopi-
cally to determine the proportion of wells exhibiting cytopathic effect
(CPE). A duplicate sample was subjected to a freeze-thaw, and then dilu-
tions of this sample (100,000 to 12,000 cell equivalents/well) were cul-
tured on MEF monolayers as described above to measure the level of
cell-associated preformed virus. To calculate the frequency of cells reacti-
vating from latency, the log10 percentage of wells with no CPE was plotted
against the number of cells per well. The Poisson distribution predicts that
if an average of one cell per well is latently infected, then 37% of wells will
have no CPE. Thus, the frequency of latently infected cells was read from
the number of cells per well, giving 37% of wells with no CPE. The fre-
quency of preformed virus was 1 per 105 cell equivalents in most cases
and never greater than 1 per 4.6  104 cell equivalents.
Determination of the frequency of latently infected cells by limiting-
dilution PCR (LDA-PCR) analysis. To determine the frequency of cells
carrying the MHV-68 genome, nested PCR assays for MHV-68 gene 50
were performed on serial dilutions of cells by using a previously published
method, with slight modifications (21). Briefly, test cells were thawed,
washed, resuspended in an isotonic solution, and counted. Starting at 104
cells/reaction mixture, cells were serially diluted 3-fold in a background of
uninfected NIH 3T3 cells such that a total of 104 cells were present in each
well (10-l total volume) and plated in a 96-well PCR plate at 12 wells/
sample per experiment. Single copies of a plasmid containing MHV-68
gene 50 in a background of 3T3 cells were included as positive controls to
verify sensitivity. 3T3 samples with no plasmid were included as negative
controls. After overnight lysis of cells with proteinase K, round-one PCR
was performed in 20 l/reaction. A nested PCR (30 cycles) was performed
following addition of 10 l of round-two reaction buffer to the same well,
and nested products were visualized on a 2% agarose gel.
Statistical analysis. Statistical differences were determined using Stu-
dent t tests or two-way analysis of variance (ANOVA) using GraphPad
Prism, version 6, software (GraphPad, La Jolla, CA).
RESULTS
miR-155 is not required for MHV-68 replication. To evaluate the
role of miR-155 in MHV-68 replication, we infected wild-type
(WT) C57BL/6 mice alongside miR-155 knockout (KO) mice
with WT MHV-68 intranasally. Viral lung titers were determined
at 7, 8.5, and 10 dpi by standard plaque assay. Titers in the lungs of
both groups were similar at all time points tested, declining to-
ward the limit of detection by 10 dpi (Fig. 1). These data indicate
that miR-155 is dispensable for acute viral replication and control
of MHV-68 replication in vivo.
MHV-68 infection induces BIC expression in germinal cen-
ter B cells. miR-155 expression has been shown to be upregulated
in both activated T and B cells as well as in EBV-transformed cell
lines and clinically isolated B cell lymphoma samples (22–25). We
first asked whether there would be a similar induction of miR-155
expression in GC B cells, the target cell population, following pri-
mary MHV-68 infection. To address this question we utilized
heterozygous BIC/miR-155 knockout lacZ reporter mice, which
allowed for detection of the transcriptional activity of the BIC
promoter, the transcriptional unit giving rise to mature miR-155
transcripts, while preserving one intact copy of the BIC gene (24,
26). Several studies have shown that BIC transcription is directly
correlated with expression of the mature miR-155 transcript (14–
16). Splenocytes were harvested at 14 days postinfection (dpi) and
were incubated with the fluorescent -galactosidase substrate res-
orufin -D-galactopyranoside. In order to compare miR-155 ex-
pression levels in both MHV-68-infected and uninfected GC B
cells in the same animal, we utilized a transgenic virus harboring
an EYFP-H2b fusion protein to detect cells that were latently in-
fected with MHV-68 (Fig. 2A) (27). Using this system we deter-
mined that BIC/miR-155 transcription was upregulated in MHV-
68-infected GC B cells compared to levels in their uninfected
counterparts (Fig. 2B and C).
miR-155 deficiency leads to an aberrant GC response follow-
ing MHV-68 infection. miR-155 has been shown to play an im-
portant role in the generation of germinal center responses in
Peyer’s patches and after immunization with model antigens (26,
FIG 1 miR-155 is not required for MHV-68 replication. WT C57BL/6 (n  4)
or miR-55 KO (n  4) mice were infected with WT MHV-68 intranasally.
Lungs were harvested at 7, 8.5, or 10 dpi (D7, D8.5, or D10, respectively), and
lung homogenates were subjected to a standard plaque assay to determine viral
titers. The dotted line indicates the threshold of detection. Data are represen-
tative of two independent experiments. Bars show standard deviations.
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28). However, it is not clear whether this requirement is altered
following viral infection and particularly in infections such as
those with MHV-68 that drive a potent splenic germinal center
response. To address this question, miR-155 KO and WT
C57BL/6 mice were infected with WT MHV-68 intranasally.
Spleens were harvested at 14 dpi and analyzed by flow cytometry
using the phenotypic markers indicated in Fig. 3. The GC B cell
population was measured by surface expression of GL7 and CD95
on CD19 B cells (Fig. 3A). Though total B cell numbers did not
differ between groups (data not shown), the proportion and ab-
solute numbers of GC B cells were found to be reduced signifi-
cantly in the miR-155 KO animals (Fig. 3B and C).
It has become well established that T follicular helper (Tfh)
cells are necessary for the development of a proper germinal center
response and that this response in turn fuels the differentiation of
more Tfh cells (29, 30). The Tfh cell response has been reported to
be necessary for optimal latency establishment in MHV-68 infec-
tion (31); therefore, we tested whether miR-155 was necessary for
this process. Tfh cell populations in mice can be readily detected
using surface expression of CD4 and high expression of both
CXCR5 and PD-1 (Fig. 3D). We detected a significant decrease in
both the proportions and absolute numbers of these cells in our
miR-155 KO animals compared to levels in WT C57BL/6 controls
(Fig. 3E and F). These cells were confirmed to be Tfh cells by
increased nuclear expression of the transcription factor BCL-6
and also by increased surface expression of the costimulatory mol-
ecule ICOS (Fig. 3G and H), increases which are consistent with
their identity as Tfh cells (29, 32, 33). Interestingly, we also ob-
served a statistically significant decrease in the level of ICOS ex-
pression in the miR-155 KO cells compared to the level in WT
C57BL/6 cells (Fig. 3H). Taken together with the reduced germi-
nal center response, these data confirm that miR-155 is required
for an optimal germinal center reaction in the presence of the
strong stimulation provided by gammaherpesvirus infection.
miR-155 KO mice display a normal MHV-68-specific anti-
body response despite having fewer antibody-producing cells.
Because we observed a reduction in germinal center responses
during MHV-68 infection, we next examined the frequency of
plasma cell formation in the spleens of these mice. At 14 dpi there
was a reduction in both the proportion and absolute number of
CD138 plasma cells in the spleens of miR-155 KO animals com-
pared to levels in WT C57BL/6 controls (Fig. 4A to C). Isotype-
switched B cells are also associated with the development of, and
transition through, the germinal center response. Therefore, we
next measured the frequency of class-switched B cells using an
antibody cocktail to determine surface expression of IgM, IgA,
IgG1, or IgG2a. At 14 dpi there was a statistically significant de-
crease in the proportion of isotype-switched B cells in the spleens
of miR-155 KO mice compared to levels in the WT C57BL/6 con-
trols (Fig. 4D). Taken together with our GC observations, these
data indicate that miR-155 is necessary for an optimal B cell re-
sponse to MHV-68 infection.
The observed decrease in both the number of antibody pro-
ducing cells and proportion of isotype-switched B cells in the miR-
155 KO mice suggested that there would be a concomitant defect
in antibody production. To address this, we tested whether the
neutralizing antiviral antibody response was affected by miR-155
deficiency. We performed an in vitro, MHV-68-specific antibody
neutralization assay, which measures the ability of serum antibody
to neutralize MHV-68. We found that miR-155 KO animals were
able to mount a neutralizing antibody response to MHV-68 that
was comparable to that of WT mice even though they have fewer
total antibody-producing cells (Fig. 4E), and this correlated with
equivalent levels of total serum IgG levels in these mice (Fig. 4F).
The requirement for miR-155 in the germinal center re-
sponse is B cell intrinsic. miR-155 knockout mice lack this
miRNA in all cells; therefore, it is not possible to distinguish be-
tween cell-intrinsic effects and indirect effects due to miR-155
deficiency in other cell types. To address cell-intrinsic effects, we
generated mixed-bone marrow (BM) chimeras using a 1:1 mix-
ture of WT C57BL/6 and miR-155 KO BM injected into lethally
irradiated, congenically distinct recipients. These mice possess
both WT and miR-155-deficient T and B cell populations, distin-
guishable by congenic markers. As cells of both genotypes are
present in the same animal, cell-extrinsic effects are controlled for,
allowing measurement of the phenotype due to cell-intrinsic ef-
fects alone. Following engraftment at 5 weeks posttransplant,
these animals exhibited similar proportions and numbers of B and
FIG 2 miR-155 is upregulated in MHV-68-infected GC B cells. The miR-155 KO locus contains a -galactosidase (LacZ) reporter gene in exon 2 of the BIC gene.
miR-155-heterozygous mice (n  6) were infected with an MHV-68-H2bYFP reporter virus intranasally. Splenocytes were harvested at 14 dpi. (A) Infected
(YFP) and uninfected (YFP negative [YFP]) populations were determined from the GC B cell compartment (CD19 GL7 CD95) using flow cytometry.
Numbers show the percentages of cells in the gates shown. SSC, side scatter. (B) Representative histogram of the mean fluorescence intensity (MFI) of -Gal
expression gated on infected (red) and uninfected (blue) GC B cells. The dotted peak represents the no-substrate control. (C) Quantification of -Gal expression,
with each pair of points representing samples from a single mouse. Plots are representative of two independent experiments. ****, P  0.0001, as determined
using Student’s t test.
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FIG 3 miR-155 deficiency leads to an aberrant GC response following MHV-68 infection. WT C57BL/6 and miR-155 KO mice were infected with MHV-68
intranasally. Splenocytes were harvested at 14 dpi. (A) GC B cell (GL7 CD95) populations were measured using flow cytometry. Plots were gated on the CD19
population. (B) Percentages of GC B cells in WT C57BL/6 (n  8) and miR-155 KO (n  6) mice. (C) Absolute numbers of GC B cells within the total CD19
B cell population. (D) T follicular helper (Tfh) cell (PD-1 CXCR5) populations were measured using flow cytometry. Plots were gated on the CD4
population. (E) Percentages of Tfh cells in WT C57BL/6 (n  8) and miR-155 KO (n  6) mice. (F) Absolute numbers of Tfh cells within the CD4 T cell
population. (G) Representative histograms of ICOS staining (top) and BCL-6 staining (bottom). Black peaks, Tfh cells; gray peaks, non-Tfh cells; dotted peaks,
isotype. (H) Tfh cells express higher levels of ICOS (top) and BCL-6 (bottom) than non-Tfh cell populations. Each point represents data from an individual
mouse. Data are representative of three independent experiments. MFI, mean fluorescence intensity. ***, P  0.001; ****, P  0.0001, as determined using
Student’s t test.
Role of miR-155 in MHV-68 Latency
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T cells (CD19 and CD3, respectively) (data not shown). Fol-
lowing intranasal infection of these mixed chimeric animals with
WT MHV-68, there again was a 2-fold decrease in both the pro-
portion and absolute number of GC B cells at 14 dpi (Fig. 5A). As
expected, this 2-fold decrease in the GC response led to a concom-
itant decrease in the proportion and number of plasma cells in the
spleen at 14 dpi (Fig. 5B). Additionally, there was also a similar
decrease in the proportion and number of Tfh cells in MHV-68-
infected mixed chimeric animals (Fig. 5C), indicating a cell-in-
trinsic role for miR-155 for efficient Tfh cell responses. Taken
together, these data indicate that miR-155 is required to form an
optimal germinal center response during gammaherpesvirus in-
fection and that this requirement is intrinsic to both B and Tfh
cells.
miR-155 is dispensable for the efficient establishment of
latency in MHV-68 infection. It is well recognized that the gam-
maherpesviruses preferentially attack the germinal center B cell
compartment in order to establish latency and gain access to the
long-lived memory B cell pool (2, 3). Since a decrease in germinal
center B cells was seen in miR-155 KO mice compared with the
level in WT C57BL/6 mice (Fig. 3), we examined whether this
would have an effect on the establishment of latency in MHV-68
infection. To address this question we determined the frequency
of cells harboring viral genome at the peak of latency (14 dpi) in
miR-155-deficient and WT C57BL/6 mice, using a limiting-dilu-
tion PCR (LDA-PCR) approach as previously described (21). The
data are plotted as the percentages of wells that contain viral ge-
nome (PCR positive). We found that the frequencies of cells har-
boring viral genome were similar between miR-155 KO animals (1
in 750 cells) and the WT C57BL/6 controls (1 in 500 cells) at the
peak of latent infection (Fig. 6A). To confirm these data, we uti-
lized a recombinant virus harboring an EYFP-H2b fusion protein
which allowed us to measure the proportion of cells harboring
latent virus on a per-cell basis (27). Within the GC B cell compart-
ment (CD19 GL7 CD95) at 14 dpi, there was no difference in
the proportions of YFP-positive (YFP) cells between the miR-
155 KO animals and the WT C57BL/6 controls, indicating simi-
larly sized populations of latently infected cells (Fig. 6B). The same
was true when mixed chimeric animals were analyzed (Fig. 6C).
Finally, when GC B cells were sorted from mixed chimeric animals
and viral genome copy numbers were measured by quantitative
PCR (qPCR) specific for MHV-68 ORF50, there was again no
difference in the latent viral load between the miR-155 KO and
WT C57BL/6 control animals (Fig. 6D). Interestingly, there was a
statistically significant difference in viral DNA burdens in the
non-GC population between WT and miR-155 KO animals; how-
ever, this represents a very small proportion of the total latent
virus burden. These data also confirmed previous studies which
documented that the majority of viral DNA resides in the GC B
cell compartment rather than in other CD19 populations (2, 3).
miR-155 is required for efficient reactivation from latency.
Given that miR-155 KO mice were able to establish latency at
levels comparable to those of WT C57BL/6 mice, we next assessed
the reactivation efficiency of cells from miR-155 KO mice using an
ex vivo reactivation assay (21). This assay showed an approximate
50-fold decrease in the ability of miR-155 KO cells to reactivate
from latency (1 in 50,000) compared to the ability in WT C57BL/6
control mice (1 in 1,000) (Fig. 7A). In contrast, the frequencies of
FIG 4 miR-155 KO mice display a normal MHV-68-specific antibody response even though they have fewer antibody-producing cells. WT C57BL/6 and
miR-155 KO mice were infected with MHV-68 intranasally. Splenocytes were harvested at 14 dpi. (A) Plasma cell (B220 CD138) populations in the spleen
were measured using flow cytometry. Cells were gated on the CD3 B220 population. (B) Percentages of plasma cells in WT C57BL/6 (n  8) and miR-155 KO
(n  6) mice. (C) Absolute numbers of plasma cells within the CD3 B220 population. (D) Percentages of isotype-switched (IgM/IgG1/IgG2a/IgA) B
cells in WT C57BL/6 (n  7) and miR-155 KO (n  7) mice. Cells were gated on CD19 cells. (E and F) Serum samples from WT C57BL/6 (n  4) and miR-155
KO (n  4) mice were harvested at 28 dpi; their ability to neutralize MHV-68 was measured (E), and the total serum IgG levels were detected by ELISA (F). **,
P  0.01; ****, P  0.0001, as determined using Student’s t test.
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viral genome-bearing cells were not significantly different, as de-
termined by LDA-PCR on samples from the same mice (1 in 400
for WT compared to 1 in 100 for miR-155 KO mice) (Fig. 7B).
These data therefore indicate a significant defect in the reactiva-
tion efficiency of miR-155-deficient cells.
DISCUSSION
The herpesviruses are unique in that they encode more micro-
RNAs than most other virus families. The gammaherpesviruses
are chief among these, encoding as many as 44 viral miRNAs (34,
35). Both virus-encoded and cellular miRNAs can alter the tran-
scription of viral and cellular genes during infection. Of particular
interest, KSHV encodes a viral homolog of the cellular miR-155
and has been shown to regulate a common set of target genes (9,
10). On the other hand, EBV does not encode a viral homolog but,
instead, is able to induce expression of cellular miR-155, which
has been shown to promote enhanced cell survival and immortal-
ization (14, 17, 36). Thus, the human gammaherpesviruses use
two different strategies to regulate miR-155 target genes.
Due to the narrow host tropism of the human gammaherpes-
viruses, all previous studies utilizing EBV infection were per-
formed in vitro and only measured the effect of miR-155 inhibi-
tion after latent infection was established. Recent work has shown
that gene expression profiling using in vitro cell lines does not
always correlate with expression in the equivalent cells when they
are infected in vivo (37). To date, there have been no studies ad-
dressing an in vivo role for miR-155 in infection or pathogenesis
following gammaherpesvirus infection. The work discussed here
sought to examine whether latency establishment is affected by the
absence of miR-155 in vivo. MHV-68 has become a critical model
system in which to study such in vivo questions. Here, we show
that, like EBV, MHV-68 is able to induce BIC expression in la-
tently infected cells. Additionally, although there is a cell-intrinsic
role for miR-155 in the GC response following MHV-68 infection,
it is dispensable for latency establishment. We also show a novel
role for miR-155 in reactivation from latency, a crucial step in the
viral life cycle.
Early work found that miR-155 deficiency led to both fewer
and smaller germinal centers in the gut-associated lymphoid tis-
sue of naive mice and in secondary lymphoid tissue following
vaccination with model antigens, indicating its critical role in the
germinal center response (26, 28). Our finding of a cell-intrinsic
role for miR-155 in the GC response is consistent with these data,
as well as with data from a more recent study following infection
with attenuated Salmonella, which showed a B cell-intrinsic role
for miR-155 in both the generation of long-lived plasma cells and
in isotype switching and affinity maturation (38).
BCL-6 is a critical transcription factor for the development of
the Tfh cell population (29, 32). Interestingly, despite the fact that
we found BCL-6 to be expressed equivalently in WT and miR-155
FIG 5 The requirement for miR-155 in the GC response is B cell intrinsic. Mixed-bone marrow chimeric mice were infected with WT MHV-68 intranasally.
Splenocytes were harvested at 14 dpi. Congenic markers were used to distinguish WT (CD45.1) from miR-155 KO (CD45.2) cells. Percentages (left) and
absolute numbers (right) of GC B cells (A), plasma cells (B), and Tfh cells (C) are shown. Each point represents data from an individual mouse. Data are
representative of three independent experiments. ***, P  0.001; ****, P  0.0001, as determined using Student’s t test.
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KO animals, we found a significant decrease in the proportion and
number of Tfh cells in miR-155 KO mice. This is consistent with a
recent study in a model of chronic inflammation showing regula-
tion of Tfh cell numbers by miR-155 through both NF-	B and
mTOR signaling (39). Since Tfh cells are needed to help drive the
GC response, it is tempting to conclude that the deficiency in
the GC response that we see in our miR-155 KO animals is due to
the deficiency in the Tfh cell population. However, data generated
from our chimeric animals showing cell-intrinsic roles for miR-
155 in both the B cell and Tfh cell compartments negate this con-
clusion. Consistent with these data, previous studies showed that
when miR-155 was deleted only within the T cell population, no
deficit in the number of GC B cells was seen following ovalbumin
(OVA) immunization (39). Interestingly, we also observed a sig-
nificant decrease in surface ICOS expression on the Tfh cells from
miR-155 KO mice. ICOS deficiency has been shown not only to
cause a severe reduction in the number of T helper cells within
the GC but also to mimic severe immunodeficiencies in hu-
mans (40, 41).
Several studies have shown that EBV induces miR-155 expres-
sion through induction of its host gene, BIC, following infection
and that this upregulation is induced by viral genes (14, 15, 42, 43).
Here, we show that MHV-68 is also able to induce BIC/miR-155
expression in infected GC B cells following infection, implying
that this molecule may play a role in viral pathogenesis. We found
no difference in viral lung titers at 7 dpi when miR-155 was absent,
indicating that this molecule is not necessary for acute viral repli-
cation in the lung. This is in contrast to in vitro data from EBV and
other viral systems, where miRNAs have been shown to play an
inhibitory role in viral replication (44–47).
High expression of miR-155 in latently infected cells and in
EBV-associated tumors suggests that miR-155 plays an important
FIG 6 miR-155 is dispensable for the efficient establishment of latency in
MHV-68 infection. Mice were infected with WT MHV-68 or the MHV-68 –
H2bYFP reporter virus intranasally. Splenocytes were harvested at 14 dpi. (A)
The frequency of cells harboring viral genome was determined using LDA-
PCR. Flow cytometry was used to determine the proportion of cells harboring
the viral genome from WT C57BL/6 (n  8) or miR-155 KO (n  6) mice (B)
or mixed chimeric mice (n  6) (C) infected with MHV-68 –H2BYFP. (D)
Mixed chimeric mice (n  6) were infected with WT MHV-68, and spleens
were pooled for sorting. DNA from sorted cell populations was subjected to
qPCR analysis with primers specific to viral ORF50. Each point represents an
individual mouse. Data represent two to three independent experiments. **,
P  0.01; ***, P  0.001; ns, not significant (determined using Student’s t test).
FIG 7 miR-155 is required for efficient reactivation from latency. WT
C57BL/6 (n  4) or miR-155 KO (n  4) mice were infected with WT
MHV-68 intranasally. Splenocytes were harvested at 14 dpi for quantification
of the frequency of cells reactivating virus (A) and the frequency of viral ge-
nome-positive cells (B) by LDA-PCR. Data are representative of two indepen-
dent experiments. **, P  0.01, as determined using Student’s t test.
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role in maintaining latency. However, it has been shown that the
different stages of latency seen in EBV infection are associated
with differing levels of miR-155 expression. During the first few
weeks of infection, EBV initiates a growth program, termed la-
tency III, which includes all nine latency-associated genes. These
genes provide proliferation, migration, and survival signals for the
activated B cells. During this growth stage, miR-155 was found to
be highly expressed. However, following the growth phase, when
infected cells exhibit the latency I phenotype and only one of the
nine proteins is still expressed (EBNA-1), miR-155 expression is
downregulated, resulting in very low levels of both BIC transcrip-
tion and of mature miR-155 transcripts (42, 48). Early (14 dpi)
latency in the MHV-68 model is believed to be analogous to la-
tency III of EBV, with a relatively broad expression of latency-
associated genes. Therefore, our observations of elevated BIC/
miR-155 expression at this time point are consistent with miR-155
upregulation in EBV latency III. Due to the low frequencies of
latently infected cells at later times postinfection and to technical
limitations in directly identifying latently infected cells at these
late time points, we are currently unable to determine whether
BIC/miR-155 is downregulated in long-term latently infected
cells.
In this study, we report a 2-fold deficit in the target GC B cell
population in miR-155 KO animals. However, we were surprised
to find that when this decrease is taken into account, there was no
significant reduction in the proportion of latently infected cells,
indicating that miR-155 is dispensable for latency establishment.
This was an interesting in vivo finding because both induced cel-
lular miR-155 and the virally encoded orthologue have been
shown to indirectly facilitate human gammaherpesvirus persis-
tence in vitro. They are thought to act through targeting genes
responsible for the expansion of the target cell population (17, 43,
49–51) and for inhibiting apoptosis through the regulation of viral
genes (52, 53). This observation raises the important question of
whether miR-155 is necessary for in vivo B cell latency in EBV and
KSHV infection. Several other miRNAs have also been reported to
influence latent gammaherpesvirus infection. For example, in
EBV, multiple viral miRNAs have been found to be important in
the survival of latently infected cells (54–56). The same is true for
KSHV (57–59). Additionally, a recent study found that deletion of
all 14 MHV-68-encoded miRNAs led to attenuated latency estab-
lishment (37), indicating that other viral miRNAs are able to pro-
mote latency establishment in several gammaherpesvirus infec-
tions.
Viral miRNAs have also been shown to be important for gam-
maherpesvirus reactivation from latency, typically by playing in-
hibitory roles. This is mediated either by direct repression of Rta
or Zta, viral transcription factors that initiate lytic cycle replica-
tion, or indirectly through repression of the pathways leading to
transcription of these factors (60–64). The KSHV homolog of
miR-155, miR-K12-11, specifically was shown to inhibit Rta by
inhibiting transcription factors known to activate the Rta pro-
moter (64).
In contrast, the role of cellular miRNAs is more complex. Some
inhibit reactivation through targeting of Rta or other EBV reacti-
vation genes (65, 66). However, others have been found to en-
hance reactivation through the suppression of ZEB1 and ZEB2,
which have been shown to bind to an inhibitory element in the Zta
promoter (67, 68). Our finding that the lack of cellular miR-155
reduces MHV-68 reactivation efficiency may involve a mecha-
nism similar to that of the latter case, which will be a focus of
future studies.
Another aspect of gammaherpesvirus reactivation that has
been well documented is the role that B cell maturation and dif-
ferentiation play in this process (69, 70). Plasma cell differentia-
tion was linked to virus reactivation in human gammaherpesvirus
infection through the induction of the plasma cell transcription
factor, XBP-1, which was found to induce a lytic switch and result
in viral reactivation (71, 72). In MHV-68 infection XBP-1 was
found to transactivate Rta in vitro; however, it was dispensable for
reactivation after in vivo infection. In contrast, IRF4 was found to
be essential for reactivation in vivo following MHV-68 infection
due to its requirement in the generation of plasma cells (73). In
this study, we found a cell-intrinsic defect in plasma cell differen-
tiation in the miR-155 KO mice, which led to a 2-fold difference in
the proportion and absolute number of plasma cells compared to
the levels in the WT controls. This is consistent with previous
studies (38, 74). However, this defect alone cannot explain the
roughly 50-fold difference we found in reactivation efficiency be-
tween the miR-155 KO mice and the WT controls. miR-155 must
therefore play a role in promoting reactivation, presumably by
regulating key cellular and/or viral genes associated with this pro-
cess. Future studies will be necessary to identify key miR-155 tar-
get genes that affect MHV-68 reactivation.
In conclusion, miR-155 has been shown to be important in
promoting latency in human gammaherpesvirus infection; how-
ever, the previous studies were done primarily in vitro. Here, we
present in vivo data showing that although miR-155 is dispensable
for latent infection, it plays an important role in viral reactivation.
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